The first GLP-1 agonistsintended to treat T2Dcame onto the market almost two decades ago
GLP-1 Receptor Agonists and Ocular Outcomes: Metabolic Transition, Retinal Vulnerability, and Risk-Stratified Monitoring
The average maximum dose of semaglutide was 0.77 mg, and all participants with a reported weight at week 64 lost over 5% of their body weight, and 85.3% lost over 10% of their baseline body weight
The concurrent engagement of all three receptors is hypothesised to produce complementary metabolic effects in pre-clinical models: GLP-1R activation is associated with glucose regulation and appetite modulation, GIPR activation with potentiation of GLP-1mediated responses, and GcgR activation with energy expenditure and hepatic lipid metabolism in laboratory settings
Content submitted by Janyce Gately MS, RD, LDN, CHC Want help building balanced meals that support natural GLP-1 production